Verona Pharma plc Pdmr Dealing
August 21 2017 - 5:42AM
UK Regulatory
TIDMVRP TIDMVRP
LONDON, Aug. 21, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP)
(NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical
company focused on developing and commercializing innovative therapies
for respiratory diseases, announces that, on August 17, 2017, Dr. David
Ebsworth, Non-Executive Chairman of the Company, purchased 8,130
ordinary shares of 5 pence each in the Company (the "Ordinary Shares")
at a price of 122.5 pence per Ordinary Share. Following the acquisition,
Dr. Ebsworth will have an interest in the Company of 125,787 Ordinary
Shares, representing 0.12% of the Company's issued share capital.
The notification of dealing form can be found below.
For further information, please contact:
Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer info@veronapharma.com
N+1 Singer (Nominated Adviser and UK Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / James White
FTI Consulting (UK Media and Investor Tel: +44 (0)20 3727 1000
enquiries)
Simon Conway / Natalie Garland-Collins veronapharma@fticonsulting.com
ICR, Inc. (US Media and Investor enquiries)
Darcie Robinson Tel: +1 203-682-8379
Darcie.Robinson@icrinc.com
Stephanie Carrington Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name David Ebsworth
2 Reason for the notification
a) Position/status Non-Executive Chairman
b) Initial Initial notification
notification/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Verona Pharma plc
b) LEI 213800EVI6O6J3TIAL06
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
a) Description of the Ordinary Shares of 5 pence each
financial instrument,
type of instrument
Identification code GB00BYW2KH80
b) Nature of the David Ebsworth purchased 8,130 Ordinary Shares
transaction
c) Price(s) and volume(s) Price(s) Volume(s)
122.5 pence per Ordinary 8,130 Ordinary Shares
Share
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 17 August 2017
f) Place of the transaction London Stock Exchange, AIM
This announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the information
contained therein.
Source: Verona Pharma plc via Globenewswire
http://www.veronapharma.com/
(END) Dow Jones Newswires
August 21, 2017 05:41 ET (09:41 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Apr 2024 to May 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From May 2023 to May 2024